» Articles » PMID: 7551659

The Effect of Systemic Lupus Erythematosus and Long-term Steroid Therapy on Bone Mass in Pre-menopausal Women

Overview
Journal Br J Rheumatol
Specialty Rheumatology
Date 1995 Aug 1
PMID 7551659
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of our study was to assess bone mineral density (BMD) in pre-menopausal women with systemic lupus erythematosus (SLE) and the influence of disease activity and use of corticosteroids. Lumbar and femoral BMD were measured in 43 patients with SLE (28 on regular steroid therapy, 15 with recent onset, non-treated) and compared with 43 healthy women matched for age. In addition, 21 SLE patients treated with corticosteroids were followed-up with a mean of 36.6 +/- 12.7 months. BMD was significantly lower in SLE patients with prednisone doses > or = 7.5 mg/day than those of recent onset (lumbar: 1.07 +/- 0.11 vs 1.15 +/- 0.13, P = 0.039; femur: 0.85 +/- 0.13 vs 0.98 +/- 0.21, P = 0.034) and the control group (lumbar: 1.07 +/- 0.11 vs 1.13 +/- 0.10, P = 0.040; femur: 0.85 +/- 0.13 vs 0.93 +/- 0.10, P = 0.028). In addition, 18% of SLE steroid users had osteoporosis. Lumbar and femoral BMD were inversely correlated with the time of treatment and the cumulative doses of prednisone. There were no significant BMD changes during the 3-yr follow-up period. In conclusion, in SLE pre-menopausal patients lumbar and femoral BMD is decreased and related to long-term corticosteroid therapy.

Citing Articles

A Retrospective Analysis of Longitudinal Changes in Bone Mineral Density in Women with Systemic Lupus Erythematosus.

Mendoza-Pinto C, Garcia-Carrasco M, Juarez-Melchor D, Munguia-Realpozo P, Etchegaray-Morales I, Santiago-Martin N Calcif Tissue Int. 2021; 109(4):363-371.

PMID: 33864471 DOI: 10.1007/s00223-021-00845-0.


Osteoporosis in Systemic Lupus Erythematosus - Correlations with Disease Activity and Organ Damage.

Barbulescu A, Vreju F, Criveanu C, Rosu A, Ciurea P Curr Health Sci J. 2018; 41(2):109-114.

PMID: 30364875 PMC: 6201199. DOI: 10.12865/CHSJ.41.02.04.


Bone mineral density and vertebral fractures in patients with systemic lupus erythematosus: A systematic review and meta-regression.

Mendoza-Pinto C, Rojas-Villarraga A, Molano-Gonzalez N, Jimenez-Herrera E, Leon-Vazquez M, Montiel-Jarquin A PLoS One. 2018; 13(6):e0196113.

PMID: 29897913 PMC: 5999233. DOI: 10.1371/journal.pone.0196113.


Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.

Seguro L, Casella C, Caparbo V, Oliveira R, Bonfa A, Bonfa E Osteoporos Int. 2014; 26(2):459-67.

PMID: 25146092 DOI: 10.1007/s00198-014-2860-9.


Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis.

Feng Z, Zeng S, Wang Y, Zheng Z, Chen Z PLoS One. 2013; 8(12):e80890.

PMID: 24324644 PMC: 3855695. DOI: 10.1371/journal.pone.0080890.